

Supplemental Table. Characteristics of Eyes with Ocular Inflammation Upon Initiation of Azathioprine, by Type of Inflammation

Ocular Inflammation	Anterior Uveitis	Intermediate Uveitis	Posterior/Panuveitis	Scleritis	Mucous Membrane Pemphigoid	Other Ocular Inflammatory Diseases	Total
Ocular complications, affected eyes, %	21 (60.0%)	20 (64.5%)	49 (54.4%)	2 (7.4%)	9 (14.1%)	1 (12.5%)	102 (40.0%)
- Prior cataract surgery*	16 (45.7%)	8 (25.8%)	19 (21.1%)	1 (3.7%)	9 (14.1%)	0 (0.0%)	53 (20.8%)
- Macular edema	5 (17.2%)	11 (37.9%)	15 (17.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	31 (17.1%)
- Epiretinal membrane	3 (10.3%)	3 (10.3%)	17 (20.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	23 (12.7%)
- Ocular hypertension (≥ 21 mmHg)	3 (8.6%)	2 (6.5%)	8 (9.6%)	1 (4.0%)	2 (9.1%)	1 (16.7%)	17 (8.4%)
- Ocular hypertension (≥ 30 mmHg)	3 (8.6%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	1 (16.7%)	5 (2.5%)
- Prior glaucoma surgery	0 (0.0%)	1 (3.2%)	4 (4.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (2.0%)
- Band keratopathy	2 (5.9%)	0 (0.0%)	2 (2.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	4 (1.8%)
- Exudative retinal detachment	0 (0.0%)	0 (0.0%)	2 (2.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.1%)
- Retinal or choroidal neovascularization	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.6%)
- Hypotony	0 (0.0%)	0 (0.0%)	1 (1.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.5%)
Anterior chamber cells (affected eye, %)							
- No cell	18 (51.4%)	20 (64.5%)	71 (78.9%)	27 (100%)	64 (100%)	8 (100%)	208 (81.6%)
- 0.5+	4 (11.4%)	5 (16.1%)	10 (11.1%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	19 (7.5%)
- 1.0+	8 (22.9%)	4 (12.9%)	4 (4.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	16 (6.3%)
- 2.0+ or more	4 (11.4%)	2 (6.5%)	5 (5.6%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	11 (4.3%)
- Missing	1 (2.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)
Vitreous cells (affected eye, %)							
- No cell	19 (54.3%)	20 (64.5%)	59 (65.6%)	27 (100%)	46 (71.9%)	8 (100%)	179 (70.2%)
- 0.5+	5 (14.3%)	9 (29.0%)	11 (12.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	25 (9.8%)
- 1.0+	5 (14.3%)	1 (3.2%)	6 (6.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (4.7%)
- 2.0+ or more	3 (8.6%)	1 (3.2%)	11 (12.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (5.9%)
- Missing	3 (8.6%)	0 (0.0%)	3 (3.3%)	0 (0.0%)	18 (28.1%)	0 (0.0%)	24 (9.4%)
Vitreous haze (affected eye, %)							
- None	31 (88.6%)	23 (74.2%)	70 (77.8%)	27 (100%)	46 (71.9%)	8 (100%)	205 (80.4%)
- 0.5+	0 (0.0%)	6 (19.4%)	9 (10.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	15 (5.9%)
- 1.0+	2 (5.7%)	2 (6.5%)	8 (8.9%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	12 (4.7%)
- Missing	2 (5.7%)	0 (0.0%)	3 (3.3%)	0 (0.0%)	18 (28.1%)	0 (0.0%)	23 (9.0%)

* prior cataract surgery included pseudophakic and aphakic patients at baseline

Note: The denominator in each of these was variable depending availability of data collection at outset of azathioprine therapy.